← NewsAll
Blood glucose monitor uses breath sensing and has entered clinical trials
Summary
The PreEvnt Isaac is a pocket-sized breath-based device that measures volatile organic compounds such as acetone to track biomarkers linked to blood glucose; it has entered human clinical trials at Indiana University comparing its readings with traditional blood sugar monitoring and is being positioned for FDA review in the coming year.
Content
The PreEvnt Isaac is a pocket-sized device presented at CES 2026 that analyzes breath to detect volatile organic compounds like acetone, which can be correlated with blood glucose changes. It is designed as a noninvasive alternative to pinprick tests and subdermal continuous glucose monitors. The concept was first shown at CES 2025 and the device is named after the inventor’s grandson, who was diagnosed with type 1 diabetes as a toddler. PreEvnt began human clinical trials at Indiana University to compare Isaac’s performance with traditional blood sugar monitoring and is preparing for regulatory review.
Key details:
- The device measures volatile organic compounds in breath, including acetone, rather than sampling blood or tissue.
- The Isaac is described as about the size of a quarter and intended to be carried or worn on a lanyard.
- The project was inspired by the inventor’s grandson, who was diagnosed with type 1 diabetes at age two.
- PreEvnt and the inventor previously displayed the concept at CES 2025.
- Human clinical trials at Indiana University are underway and compare Isaac’s readings with standard blood glucose monitoring.
- The trials are being conducted with an eye toward U.S. Food and Drug Administration review in the upcoming year.
Summary:
The Isaac represents a breath-based, noninvasive approach to tracking biomarkers tied to blood glucose that is now in clinical testing. Indiana University trials are comparing its measurements to conventional methods, and the company plans to seek FDA review in the coming year. Further availability and use will depend on the results of those trials and subsequent regulatory decisions.
